India CRAMS Market Outlook to 2018 - Surging Demand for Contract Drug Discovery and Research Services
The industry research publication titled ‘India CRAMS Market Outlook to 2018 – Surging Demand for Contract Drug Discovery and Research Services’ presents a comprehensive analysis of market size by value of CRAMS services in India. The report entails the market share analysis and company profiles of major players in the CRAMS industry. The future analysis and segmentation by drugs and devices and therapeutic areas have also been discussed in each of the sub-segment.
The CRAMS industry in India has grown at a CAGR of 17.8% during 2007-2013 registering a market size of USD ~ billion in value terms in 2013. Some of the major competitors of India include China, Russia, Brazil and Taiwan. Escalating costs, growth of companies producing generic drugs, declining research and development productivity and regulatory pressures have encouraged the global pharmaceutical companies to offshore research and development activities to emerging countries such as India and China. Indian CRAMS market has been dominated by the contract manufacturing services which contributed more than half of the industry revenues during 2007-2013. The CMO market registered revenue of USD ~ billion in 2013, growing at a CAGR of 16.3% during 2007-2013. The contract manufacturing services has benefitted from advantages such as tax breaks with respect of setting up of facilities in particular areas, economies of scale and others. The contract research market in India contributed 40.0% to CRAMS industry in 2013 with revenues of USD ~ billion which grew at a CAGR of ~% during 2007-2013. A large number of Indian CROs are involved in providing late stage discovery and drug development services. The Indian CRAMS industry is dominated by drugs market which contributed 60.0% of the CRAMS industry in 2013. The major therapeutic areas being focused on include cardiovascular diseases, metabolic disorders, oncology and others. The CRAMS industry of India comprises of a large number of operating players making it a highly fragmented industry. Some of the key players of the Indian CRAMS industry include Divis Laboratories, Jubilant, Dishman, Biocon and GVK Biosciences.
With the government of India planning to embark on a multimillion dollar initiative to promote innovation in the pharmaceutical industry of the country, the Indian CRAMS market revenue is expected to reach USD ~ billion by 2018, growing at a double digit compounded growth rate of 22.2% during 2013-2018.
KEY TOPICS COVERED IN THE REPORT
The CRAMS industry in India has grown at a CAGR of 17.8% during 2007-2013 registering a market size of USD ~ billion in value terms in 2013. Some of the major competitors of India include China, Russia, Brazil and Taiwan. Escalating costs, growth of companies producing generic drugs, declining research and development productivity and regulatory pressures have encouraged the global pharmaceutical companies to offshore research and development activities to emerging countries such as India and China. Indian CRAMS market has been dominated by the contract manufacturing services which contributed more than half of the industry revenues during 2007-2013. The CMO market registered revenue of USD ~ billion in 2013, growing at a CAGR of 16.3% during 2007-2013. The contract manufacturing services has benefitted from advantages such as tax breaks with respect of setting up of facilities in particular areas, economies of scale and others. The contract research market in India contributed 40.0% to CRAMS industry in 2013 with revenues of USD ~ billion which grew at a CAGR of ~% during 2007-2013. A large number of Indian CROs are involved in providing late stage discovery and drug development services. The Indian CRAMS industry is dominated by drugs market which contributed 60.0% of the CRAMS industry in 2013. The major therapeutic areas being focused on include cardiovascular diseases, metabolic disorders, oncology and others. The CRAMS industry of India comprises of a large number of operating players making it a highly fragmented industry. Some of the key players of the Indian CRAMS industry include Divis Laboratories, Jubilant, Dishman, Biocon and GVK Biosciences.
With the government of India planning to embark on a multimillion dollar initiative to promote innovation in the pharmaceutical industry of the country, the Indian CRAMS market revenue is expected to reach USD ~ billion by 2018, growing at a double digit compounded growth rate of 22.2% during 2013-2018.
KEY TOPICS COVERED IN THE REPORT
- The market size of the India CRAMS market in terms of value in the last years (2007 - 2013)
- India CRAMS market segmentation by CMO and CRO service
- India CRAMS market segmentation by Drugs and Devices
- India CRAMS for Drugs Market Segmentation by Therapeutic Areas
- Trends and Developments in the CRAMS market in India
- Government Rules and Regulations in the CRAMS market in India
- Competitive landscape players operating in CRAMS market of India (such as Divis, Dishman, Biocon, Jubilant and others)
- Future projections and macro economic factors of CRAMS market in India.
1. INDIA CRAMS MARKET INTRODUCTION AND SIZE, 2007-2013
2. INDIA CRAMS MARKET SEGMENTATION
2.1. By CMO and CRO, 2007-2018
2.2. India CRAMS Market Segmentation by Drugs and Devices, 2007-2018
2.2.1. India CRAMS for Drugs Market Segmentation by Therapeutic Classes, 2007-2018
3. MARKET SHARE OF MAJOR PLAYERS IN INDIA CRAMS MARKET, 2011-2013
4. COMPANY PROFILES OF MAJOR PLAYERS IN INDIA CRAMS MARKET
4.1. Jubilant Life Sciences
4.1.1. Business Overview
4.1.2. Financial Performance, 2012 and 2013
4.1.3. Business Strategies
Focus on Inorganic Expansion
4.2. Divis Laboratories
4.2.1. Business Overview
4.2.2. Financial Performance, 2010-2013
4.2.3. Business Strategies
Increased Focus on Custom Synthesis
Focus on Establishing New Capacities
4.3. Biocon
4.3.1. Business Overview
4.3.2. Financial Performance, 2010 – 2013
4.3.4. Business Strategies
Focus on Collaborative Research and Development
Focus on Insulin Strategy
4.4. Dishman Pharmaceuticals
4.4.1. Business Overview
4.4.2. Financial Performance, 2010-2013
4.4.3. Business Strategies
Focus on Mid Sized Contracts
4.5. Dr Reddy’s Laboratories (Aurigene)
4.5.1. Business Overview
4.5.2. Financial Performance, 2012 and 2013
4.5.3. Business Strategy
Focus on Collaboration for Drug Discovery and Development
5. SWOT ANALYSIS OF INDIA CRAMS MARKET
6. GOVERNMENT REGULATIONS IN INDIA CRAMS MARKET
7. TRENDS AND DEVELOPMENT IN INDIA CRAMS MARKET
Greater Focus on Contract Manufacturing
Collaboration with Foreign Players
Shift from Non-Core Functions to Core Functions for Outsourcing
8. INDIA CRAMS MARKET FUTURE OUTLOOK AND PROJECTIONS, 2014-2018
9. MACRO-ECONOMIC FACTORS AFFECTING INDIA CRAMS MARKET
9.1. Ageing Population (55 Years and Above), 2007-2018
9.2. Total Healthcare Expenditure, 2007-2018
9.3. Gross Domestic Product, 2007-2018
9.4. India Pharmaceutical Industry Revenues, 2007-2018
9.5. Personal Disposable Income, 2007-2018
10. APPENDIX
10.1. Market Definitions
10.2. Abbreviations
10.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
10.4. Disclaimer
2. INDIA CRAMS MARKET SEGMENTATION
2.1. By CMO and CRO, 2007-2018
2.2. India CRAMS Market Segmentation by Drugs and Devices, 2007-2018
2.2.1. India CRAMS for Drugs Market Segmentation by Therapeutic Classes, 2007-2018
3. MARKET SHARE OF MAJOR PLAYERS IN INDIA CRAMS MARKET, 2011-2013
4. COMPANY PROFILES OF MAJOR PLAYERS IN INDIA CRAMS MARKET
4.1. Jubilant Life Sciences
4.1.1. Business Overview
4.1.2. Financial Performance, 2012 and 2013
4.1.3. Business Strategies
Focus on Inorganic Expansion
4.2. Divis Laboratories
4.2.1. Business Overview
4.2.2. Financial Performance, 2010-2013
4.2.3. Business Strategies
Increased Focus on Custom Synthesis
Focus on Establishing New Capacities
4.3. Biocon
4.3.1. Business Overview
4.3.2. Financial Performance, 2010 – 2013
4.3.4. Business Strategies
Focus on Collaborative Research and Development
Focus on Insulin Strategy
4.4. Dishman Pharmaceuticals
4.4.1. Business Overview
4.4.2. Financial Performance, 2010-2013
4.4.3. Business Strategies
Focus on Mid Sized Contracts
4.5. Dr Reddy’s Laboratories (Aurigene)
4.5.1. Business Overview
4.5.2. Financial Performance, 2012 and 2013
4.5.3. Business Strategy
Focus on Collaboration for Drug Discovery and Development
5. SWOT ANALYSIS OF INDIA CRAMS MARKET
6. GOVERNMENT REGULATIONS IN INDIA CRAMS MARKET
7. TRENDS AND DEVELOPMENT IN INDIA CRAMS MARKET
Greater Focus on Contract Manufacturing
Collaboration with Foreign Players
Shift from Non-Core Functions to Core Functions for Outsourcing
8. INDIA CRAMS MARKET FUTURE OUTLOOK AND PROJECTIONS, 2014-2018
9. MACRO-ECONOMIC FACTORS AFFECTING INDIA CRAMS MARKET
9.1. Ageing Population (55 Years and Above), 2007-2018
9.2. Total Healthcare Expenditure, 2007-2018
9.3. Gross Domestic Product, 2007-2018
9.4. India Pharmaceutical Industry Revenues, 2007-2018
9.5. Personal Disposable Income, 2007-2018
10. APPENDIX
10.1. Market Definitions
10.2. Abbreviations
10.3. Research Methodology
Data Collection Methods
Approach
Variables (Dependent and Independent)
Multi Factor Based Sensitivity Model
Final Conclusion
10.4. Disclaimer
LIST OF FIGURES
Figure 1: India CRAMS Market Size on the Basis of Revenue in USD Billion, 2007-2013
Figure 2: India CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2007-2013
Figure 3: India CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue Contribution in Percentage, 2007-2013
Figure 4: India CRAMS Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Figure 5: Aged Population in India in Million, 2007-2018
Figure 6: India Healthcare Expenditure in USD Billion, 2007-2018
Figure 7: Gross Domestic Product of GDP in USD Billion, 2007-2018
Figure 8: India Pharmaceutical Industry Market Size on the Basis of Revenues in USD Billion, 2007-2018
Figure 9: Personal Disposable Income of India in USD Billion, 2007-2018
Figure 1: India CRAMS Market Size on the Basis of Revenue in USD Billion, 2007-2013
Figure 2: India CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2007-2013
Figure 3: India CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue Contribution in Percentage, 2007-2013
Figure 4: India CRAMS Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Figure 5: Aged Population in India in Million, 2007-2018
Figure 6: India Healthcare Expenditure in USD Billion, 2007-2018
Figure 7: Gross Domestic Product of GDP in USD Billion, 2007-2018
Figure 8: India Pharmaceutical Industry Market Size on the Basis of Revenues in USD Billion, 2007-2018
Figure 9: Personal Disposable Income of India in USD Billion, 2007-2018
LIST OF TABLES
Table 1: Benefits, Risks and Challenges Faced by India CRAMS Industry
Table 2: India CMO and CRO Market Size on the Basis of Revenue in USD Billion, 2007-2013
Table 3: India CMO and CRO Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Table 4: India CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 5: Advantages of Setting up CROs in India
Table 6: India CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue in USD Billion, 2007-2013
Table 7: India CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 8: India Crams Market Segmentation by Drugs and Devices and Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Table 9: India CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue Contribution in Percentage, 2007-2013
Table 10: India CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue in USD Million, 2007-2013
Table 11: India CRAMS for Drugs Market Segmentation on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 12: India CRAMS for Drugs Market Future Projection on the Basis of Revenue in USD Million, 2014-2018
Table 13: Number of Clinical Studies Performed in Different Therapeutic Areas in India in Numbers, 2007-2013
Table 14: Market Share of Major Players in India CRAMS Market on the Basis of Revenue in Percentage, 2011-2013
Table 15: Revenue of Major Players in India CRAMS Market in USD Million, 2011-2013
Table 16: Recent Deals in India CMO Market
Table 17: Jubilant Life Science Service Revenues in USD Million and INR Million, 2012 and 2013
Table 18: Acquisition and Expansion Profile, FY’2003 - FY’2009
Table 19: Divis Laboratories CRAMS Revenue in USD Million and INR Million, 2009 – 2013
Table 20: Biocon CRAMS Revenue in USD Billion and INR Million, 2010 – 2013
Table 21: Dishman Pharmaceutical CRAMS Revenue in USD Million and INR Million, 2010-2013
Table 22: Aurigene Revenue in USD Million and INR Million, 2012 and 2013
Table 23: Correlation Matrix for India CRAMS Market
Table 24: Regression Coefficients Output
Table 1: Benefits, Risks and Challenges Faced by India CRAMS Industry
Table 2: India CMO and CRO Market Size on the Basis of Revenue in USD Billion, 2007-2013
Table 3: India CMO and CRO Market Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Table 4: India CRAMS Market Segmentation by CMO and CRO on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 5: Advantages of Setting up CROs in India
Table 6: India CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue in USD Billion, 2007-2013
Table 7: India CRAMS Market Segmentation by Drugs and Devices on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 8: India Crams Market Segmentation by Drugs and Devices and Future Projections on the Basis of Revenue in USD Billion, 2014-2018
Table 9: India CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue Contribution in Percentage, 2007-2013
Table 10: India CRAMS for Drugs Market Segmentation by Therapeutic Areas on the Basis of Revenue in USD Million, 2007-2013
Table 11: India CRAMS for Drugs Market Segmentation on the Basis of Revenue Contribution in Percentage, 2014-2018
Table 12: India CRAMS for Drugs Market Future Projection on the Basis of Revenue in USD Million, 2014-2018
Table 13: Number of Clinical Studies Performed in Different Therapeutic Areas in India in Numbers, 2007-2013
Table 14: Market Share of Major Players in India CRAMS Market on the Basis of Revenue in Percentage, 2011-2013
Table 15: Revenue of Major Players in India CRAMS Market in USD Million, 2011-2013
Table 16: Recent Deals in India CMO Market
Table 17: Jubilant Life Science Service Revenues in USD Million and INR Million, 2012 and 2013
Table 18: Acquisition and Expansion Profile, FY’2003 - FY’2009
Table 19: Divis Laboratories CRAMS Revenue in USD Million and INR Million, 2009 – 2013
Table 20: Biocon CRAMS Revenue in USD Billion and INR Million, 2010 – 2013
Table 21: Dishman Pharmaceutical CRAMS Revenue in USD Million and INR Million, 2010-2013
Table 22: Aurigene Revenue in USD Million and INR Million, 2012 and 2013
Table 23: Correlation Matrix for India CRAMS Market
Table 24: Regression Coefficients Output
